TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05218148
Drug: sintilimab
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sintilimab 200mg was administered as a 30-60 min intravenous (IV) infusion every 3 weeks.3 cycles before surgery and 5 cycles after surgery.
Study: NCT05218148
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab was 8mg/kg for the first time, and 6mg/kg for the follow-up. 3 cycles before surgery and 5 cycles after surgery.
Study: NCT05218148
Drug: S-1 plus oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin 130 mg/m2 was administered IV every 3 weeks. S-1 was given orally twice daily for the first 2 weeks of each 3-week cycle. The S-1 dose was 40 mg for body surface area (BSA) \< 1.25 m2, 50 mg for BSA 1.25 to \<1.5 m2 and 60 mg for BSA ≥1.5 m2.~Body surface area \&lt;1.25m2: Tegio 40mg bid day 1 \~ 14; Body surface area 1.25 \~ \&lt;1.5m2: Tegio 50mg bid day 1 \~ 14; Body surface area ≥1.5m2: Tegio 60mg bid day 1 \~ 14; 3 cycles before surgery and 3 cycles after surgery.
Study: NCT04822701
Drug: BI 767551 intravenous
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 767551 intravenous
Study: NCT04822701
Drug: BI 767551 inhaled
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 767551 inhaled
Study: NCT05448885
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive neoadjuvant therapy with gemcitabine(1000mg per square meter on day 1,8) , cisplatin (25mg per square meter on day 1-3) and tislelizumab(200mg) every three weeks for 2 cycles before radiotherapy, then followed by concurrent IMRT and cisplatin (100mg per square meter) concurrent every three weeks during radiotherapy ,then followed by adjuvant therapy with tislelizumab(200mg) every three weeks for 13 cycles after radiotherapy
Study: NCT05053737
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One cycle of Atezolizumab will be administered by intravenous (IV) infusion at a fixed dose of 1200 mg. Atezolizumab should be administered within 7 days after initiation of of the first dose of SBRT.
Study: NCT05651373
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-30mg, po, once per day(Qd) prescribed if needed and adjusted due to patient response
Study: NCT05651373
Drug: Hydroxychloroquine
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200mg, po, twice per day (Bid) prescribed if needed and adjusted due to patient response.
Study: NCT05036421
Drug: Empagliflozin 10 milligram
Normalized name: Product containing precisely empagliflozin 10 milligram/1 each conventional release oral tablet (clinical drug)
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: antihyperglycemic medication
Study: NCT06561074
Drug: Decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given by vein
Study: NCT06561074
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given by mouth
Study: NCT06561074
Drug: Calaspargase pegol-mknl
Normalized name: calaspargase pegol-mknl
DrugBank: Calaspargase pegol (DB14730)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given by vein
Study: NCT06268977
Drug: SGLT2 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: a class of prescription medicines that are FDA-approved for use with diet and exercise to lower blood sugar in adults with type 2 diabetes.
Study: NCT05164367
Drug: Atropine sulfate gel (0.01%)
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A research nurse will measure 1 gram of gel using a calibrated measuring spoon and will provide it to the participant for self-administration.
Study: NCT05278624
Drug: Roflumilast Cream
Normalized name: Roflumilast
DrugBank: Roflumilast (DB01656)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Topical Cream
Study: NCT05963568
Drug: Polycap
Normalized name: Atriplex polycarpa pollen
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients allocated to the experimental arm will receive Two (2) (Polycap ®) taken orally once a day. A capsule of Polycap ® contains 100mg of Aspirin, 20mg of simvastatin, 12.5mg hydrochlorothiazide, 5mg of ramipril and 50mg of atenolol. Patients assigned to Polypill will have their antihypertensive agents, lipid modifiers and anti-thrombotic agents withdrawn and replaced with the Polypill if they are already receiving such treatments before enrollment.
Study: NCT06652906
Drug: Sodium phosphate powder
Normalized name: cellulose sodium phosphate Oral Powder
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After admission, the patient underwent comprehensive renal function and electrolyte tests. The first medication was taken at 7pm the day before the examination. One bag of sodium phosphate powder was diluted with 800ml or more of warm and cool water before taking. The second dose of medication should be taken at 7am on the day of operation or examination (or at least 3 hours before the examination), with the same usage as the first dose, with a 12 hour interval between each dose. The standard dose for each dose is 1 bag, until clear water like stool appears.
Study: NCT06652906
Drug: Polyethylene glycol electrolyte dispersion
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After admission, the patient underwent comprehensive renal function and electrolyte examination. The evening before the intestinal examination, 2000ml of polyethylene glycol electrolyte San III isotonic solution was taken, 250ml every 10-15 minutes, and it was taken within 2 hours. On the day of examination, 2000ml of polyethylene glycol electrolyte San III isotonic solution was taken 3-4 hours in advance until clear water like stool appeared.
Study: NCT04800159
Drug: THC Cannabis
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaporization of cannabis
Study: NCT04800159
Drug: CBD Cannabis
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaporization of cannabis
Study: NCT00002213
Drug: Abacavir sulfate
Normalized name: Abacavir Sulfate
DrugBank: Abacavir (DB01048)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00002213
Drug: Amprenavir
Normalized name: Amprenavir
DrugBank: Amprenavir (DB00701)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00002213
Drug: Efavirenz
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05540587
Drug: Edoxaban
Normalized name: Edoxaban
DrugBank: Edoxaban (DB09075)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients in the Edoxaban group take Edoxaban 60mg once daily. If any of the following conditions are present, take 30mg once daily.~* CrCl 15-50mL/min~* Body weight ≤ 60kg~* Concomitant use of P-glycoprotein inhibitor (Dronearone, Ciclosporine, Erythromycin or Ketoconazole)
Study: NCT05540587
Drug: Warfarin
Normalized name: Warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in the Warfarin group take Warfarin 2-10mg once daily, dose adjusted with the target INR 2-3. In the elderly or frail patients, a lower dose administration is allowed at the discretion of the investigator.
Study: NCT05156021
Drug: anti-VEGF
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: To explore whether adding post-vitrectomy anti-VEGF agent injection can reach a better prognosis in PDR patients with NVG who underwent PPV combined with PRP and pressure-reducing valve implantation
Study: NCT05688124
Drug: Esomeprazole
Normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Esomeprazole is administered orally
Study: NCT05200234
Drug: Nattokinase
Normalized name: Nattokinase
DrugBank: Nattokinase (DB15329)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nattokinase + standard treatment
Study: NCT04781751
Drug: insulin injection
Normalized name: diluent for insulin lispro and regular insulin INJECTION VIAL (ML)
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carpal tunnel syndrome sonagraphic injection
Study: NCT00075257
Drug: DVS-233 SR
Normalized name: rAAVrh74.MHCK7.DYSF.DV
DrugBank: S-23 (DB07419)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04598815
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Group Sirolimus: Patients will receive a first dose of Sirolimus of one 2 mg tablet on the first day, given approximately at 10 am, followed by 0.5 mg tablet per day for 12 weeks.~Group Methylprednisolone: Methylprednisolone pulse therapy will be administered for 12 weeks as follows: 500 mg iv once weekly for 6 weeks, then 250 mg iv once weekly for a further 6 weeks, for a cumulative dose 4.5 g.
Study: NCT05560230
Drug: Clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A single dose of intraoperatively administered intravenous clonidine 150 μg will be infused over 5-10 min., immediately after intubation
Study: NCT06362369
Drug: Alintegimod
Normalized name: Alintegimod
DrugBank: Alintegimod (DB18879)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alintegimod will be provided in bottles of 30 softgel capsules for oral administration
Study: NCT06362369
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab (Yervoy) will be administered via IV
Study: NCT06362369
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab (Opdivo) will be administered via IV
Study: NCT05344963
Drug: Sodium-GLucose coTransporter-2 inhibitors
Normalized name: glucose / sodium chloride
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Evaluation of the modification of conventional and advanced echocardiographic parameters, focusing on speckle tracking and three-dimensional echocardiography (optional), in patients with HFrEF after treatment with the SGLT2i drugs Dapagliflozin and Empagliflozin
Study: NCT05571319
Drug: Metformin Extended Release Oral Tablet
Normalized name: metformin Extended Release Oral Tablet
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Glucophage XR 500 mg
Study: NCT06146842
Drug: Bupivacaine Hydrochloride
Normalized name: Bupivacaine Hydrochloride
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each subject will receive allocated dose of bupivacaine
Study: NCT06525389
Drug: Liposomal Amphotericin B (LAmB)
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antifungal dosed at 10 mg/kg/day IV x one single dose.
Study: NCT06525389
Drug: Flucytosine (5FC)
Normalized name: Flucytosine
DrugBank: Flucytosine (DB01099)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antifungal dosed at 25mg/kg oral 3x daily.
Study: NCT06525389
Drug: Flucytosine (5FC) placebo pill
Normalized name: flucytosine Pill
DrugBank: Flucytosine (DB01099)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Similar in appearance to flucytosine. Also dosed at 25mg/kg oral 3x daily.
Study: NCT06525389
Drug: Deoxycholate Amphotericin B (DAmB)
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antifungal dosed at 0.7 mg/kg/day IV x 2 weeks.
Study: NCT04815148
Drug: MH004 Ia(0.1%)
Normalized name: MAGNESIUM ALUMINOMETASILICATE TYPE IA
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Spread approx. 1 g of MH004 topical cream to the upper thigh skin.
Study: NCT04815148
Drug: MH004 Ia(0.3%)
Normalized name: MAGNESIUM ALUMINOMETASILICATE TYPE IA
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Spread approx. 1 g of MH004 topical cream to the upper thigh skin.
Study: NCT04815148
Drug: MH004 Ia(1%)
Normalized name: MAGNESIUM ALUMINOMETASILICATE TYPE IA
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Spread approx. 1 g of MH004 topical cream to the upper thigh skin.
Study: NCT04815148
Drug: MH004 Ia(3%)
Normalized name: MAGNESIUM ALUMINOMETASILICATE TYPE IA
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Spread approx. 1 g of MH004 topical cream to the upper thigh skin.
Study: NCT05373615
Drug: Cefiderocol
Normalized name: Cefiderocol
DrugBank: Cefiderocol (DB14879)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: After receipt of Cefiderocol, blood samples will be collected at various time points to determine the pharmacokinetics of Cefiderocol
Study: NCT04520711
Drug: CDX-1140
Normalized name: CDX
DrugBank: Cefadroxil (DB01140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Recombinant fully human IgG2κ monoclonal antibody
Study: NCT04520711
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Humanized immunoglobulin G4 (IgG4) monoclonal antibody
Study: NCT00239252
Drug: Interferon alfacon-1
Normalized name: interferon alfacon-1
DrugBank: Interferon alfacon-1 (DB00069)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05351164
Drug: Metreleptin
Normalized name: Metreleptin
DrugBank: Metreleptin (DB09046)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Study drug for injection is supplied in a carton containing 30 vials for reconstitution. Each vial contains 11.3 mg of the study drug as a sterile, white, solid, lyophilized cake or powder to deliver 5 mg/mL of the study drug when reconstituted with 2.2 mL of water for injection (WFI).
Study: NCT00002317
Drug: Trimetrexate glucuronate
Normalized name: Trimetrexate Glucuronate
DrugBank: Trimetrexate (DB01157)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06078384
Drug: Pembrolizumab 25 mg/ml
Normalized name: pembrolizumab 25 MG/ML
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab drug product is a sterile-filtered liquid and is aseptically filled into single-use vials.~The vials contain 4 mL of sterile solution for IV infusion.
Study: NCT06078384
Drug: Paclitaxel injection
Normalized name: paclitaxel Injection
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Injectable solution for IV administration. Dose of 80 mg/m² weekly.
Study: NCT04793022
Drug: TIVA with Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Total intravenous anesthesia with propofol
Study: NCT06178601
Drug: RC48-ADC
Normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: RC48-ADC （2.0 mg/kg，intravenous (IV) infusion，Q2W）, combined with cadonilimab（AK104）
Study: NCT06178601
Drug: AK104
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: AK104（6.0 mg/kg，intravenous (IV) infusion，Q2W）combined with RC48-ADC
Study: NCT05504642
Drug: Pre-Chemo-radio-immunotherapy Treatment (Nivolumab/Ipilimumab)
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Two weeks before start of Chemo-radio-immunotherapy one administration of Nivolumab 3 mg/kg and Ipilimumab 1 mg/kg IV over 30 minutes, with a 30 minute break between Nivolumab and Ipilimumab.
Study: NCT05507112
Drug: PD-1 inhibitor
Normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Sasanlimab (DB18849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tislelizumab (3 cycles): 200mg i.v. q3w on day 1 of each cycle, and starting from the second week after the start of radiotherapy
Study: NCT06175949
Drug: HRS-7085 Tablets
Normalized name: HRS-1167
DrugBank: HRS-1167 (DB18703)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRS-7085 Tablets, PO, 2mg、5mg、8mg、10mg、12mg、15mg, QD,
Study: NCT05649956
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letrozole 2.5 mg PO daily
Study: NCT06674577
Drug: Atacicept 150 mg
Normalized name: Atacicept
DrugBank: Atacicept (DB06399)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The atacicept drug product is available as a ready to use injection solution in the following prefilled syringe (PFS) that is composed of: \*BD Hypak™ SCF™ Barrel Glass barrel 1ml long with staked needle 27G ½ 5B with Rigid Needle Shield BD260 \*BD SCF™ Stopper 1ml long W4023 Flurotec
Study: NCT05190094
Drug: Combination of Palbociclib and aromatase inhibitor (Letrozole or Anastrozole)
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A combination of Palbociclib (125 mg daily per os (3 weeks on-1 week off) with dose adaptation according to safety profile) and non-steroidal aromatase inhibitor (Letrozole (2.5mg ) or Anastrozole (1mg) daily per os).
Study: NCT00781482
Drug: eszopiclone, zolpidem, placebo
DrugBank: Eszopiclone (DB00402)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In random order, each subject will receive one study drug per visit over three visits. Visits will occur about 1 week apart. Each subject will eventually receive eszopiclone 3 mg., zolpidem 10 mg., and a placebo. PET scans will be done 1-2 hours after each dose.
Study: NCT04219046
Drug: Naloxégol oxalate
Normalized name: Naloxegol Oxalate
DrugBank: Naloxegol (DB09049)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral administration once daily
Study: NCT06086340
Drug: Palbociclib
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Palbociclib with an aromatase inhibitor therapy
Study: NCT06462105
Drug: Irinotecan Hydrochloride Liposome Injection；Carboplatin Injection；Serplulimab Injection
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cohort 1: Liposomal irinotecan: 50mg/m2, ivgtt, d1; Carboplatin AUC=5, ivgtt, d1; Serplulimab: 4.5mg/kg, ivgtt, d1; The drug was administered once every three weeks for a total of 4 cycles. After 4 cycles, serplulimab is maintained until disease progression or toxicity becomes intolerable.~Cohort 2: Etoposide: 100 mg/m2, ivgtt, d1-3; Carboplatin AUC=5, ivgtt, d1; Serplulimab: 4.5mg/kg, ivgtt, d1; The drug was administered once every three weeks for a total of 4 cycles. After 4 cycles, serplulimab is maintained until disease progression or toxicity becomes intolerable.
Study: NCT04716296
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketamine will be given for the second stage of the DBS surgery.
Study: NCT04716296
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline will be given for the second stage of the DBS surgery.
Study: NCT04927169
Drug: Interleukin-7
Normalized name: interleukin-7
DrugBank: Interleukin-7 (DB11997)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM administration at 10μg/kg twice a week for three weeks and up to 7 administrations according to Hospital length of stay
Study: NCT05819866
Drug: Leriglitazone
Normalized name: Leriglitazone
DrugBank: Leriglitazone (DB15021)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leriglitazone at a strength of 15 mg/ml. Once-daily dosing at an initial volume of 10 ml
Study: NCT04495608
Drug: Fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole 50 mg/capsule or placebo, per os during 18 weeks :~* From W0 to W2 : 1 caps/ day~* From W2 to W4 : 1 or 2 caps/day~* From W4 to W6 : 1, 2 or 3 caps/day~* From W6 to W18 : 1, 2, 3 or 4 caps/day~The number of capsules to take will be determined by 24-hours calciuria results performed every 2 weeks during the titration period (W2, W4 and W6).~During the titration period, if 24-hours calciuria is \> 0.1 mmol/kg/day, fluconazole dose will be increased every 2 weeks to 50 mg per intake, with a maximum dose of 200 mg/day. If 24-hour calciuria is ≤ 0.1mmol/kg/day, fluconazole dose will remain stable.~After W6 and until the end of the study, the treatment dose will remain stable (stable period).
Study: NCT05216354
Drug: Fruquintinib
Normalized name: fruquintinib
DrugBank: Fruquintinib (DB11679)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fruquintinib will be administered as a single dose on the morning of Day 1 under fasting conditions
Study: NCT06048484
Drug: Zimberelimab
Normalized name: Zimberelimab
DrugBank: Zimberelimab (DB17505)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mg intravenously (IV)
Study: NCT06048484
Drug: Quemliclustat
Normalized name: Quemliclustat
DrugBank: Quemliclustat (DB19160)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg IV
Study: NCT06048484
Drug: Etrumadenant
Normalized name: Etrumadenant
DrugBank: Etrumadenant (DB17506)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg orally
Study: NCT06208371
Drug: Palliative Chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in this group may continue the original systemic chemotherapy regimen. Patients with tumor control after 10-12 cycles can either transition to maintenance treatment or temporarily suspend treatment until disease progression, at which point they switch to a second-line treatment regimen.The selection of second-line and subsequent treatment regimens follows CSCO guidelines and clinical practices.
Study: NCT05373914
Drug: Cudetaxestat (BLD-0409)
Normalized name: Cudetaxestat
DrugBank: Cudetaxestat (DB18203)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cudetaxestat - 250mg tablets (orally)
Study: NCT06451198
Drug: Indobufen
Normalized name: indobufen
DrugBank: Indobufen (DB12545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients meeting the criteria are randomized before discharge from the hospital and given indobufen 100mg bid and ticagrelor 90mg bid the second day after randomization. The administration shall last 12 months.
Study: NCT06451198
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients meeting the criteria are randomized before discharge from the hospital and continued aspirin 100 mg qd and ticagrelor 90mg bid. The administration shall last 12 months.
Study: NCT06451198
Drug: Ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All the patients meeting the criteria and enrolled in the study are given ticagrelor 90mg bid for 12 months.
Study: NCT04871919
Drug: Filgotinib
Normalized name: Filgotinib
DrugBank: Filgotinib (DB14845)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Tablets are administered in accordance with the product label
Study: NCT05410873
Drug: MitoQ Compound
Normalized name: BENZOIN COMPOUND
DrugBank: Benzoin (DB14020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitoquinol mesylate